Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

The role of chaperones in polyglutamine disease.

Opal P, Zoghbi HY.

Trends Mol Med. 2002 May;8(5):232-6. Review.

PMID:
12067633
2.

Protective effect of chaperones on polyglutamine diseases.

Kobayashi Y, Sobue G.

Brain Res Bull. 2001 Oct-Nov 1;56(3-4):165-8. Review.

PMID:
11719246
3.

[Molecular biology of polyglutamine diseases].

Owecki M, Kozubski W.

Postepy Hig Med Dosw. 2002;56(6):779-88. Review. Polish.

PMID:
12661407
4.

Polyglutamine diseases and molecular chaperones.

Kimura Y, Kakizuka A.

IUBMB Life. 2003 Jun;55(6):337-45. Review.

5.

Modulation of neurodegeneration by molecular chaperones.

Muchowski PJ, Wacker JL.

Nat Rev Neurosci. 2005 Jan;6(1):11-22. Review.

PMID:
15611723
6.

Emerging roles of J proteins in neurodegenerative disorders.

Gibbs SJ, Braun JE.

Neurobiol Dis. 2008 Nov;32(2):196-9. doi: 10.1016/j.nbd.2008.07.016. Epub 2008 Aug 5. Review.

PMID:
18760363
7.

Cellular defenses against unfolded proteins: a cell biologist thinks about neurodegenerative diseases.

Sherman MY, Goldberg AL.

Neuron. 2001 Jan;29(1):15-32. Review. No abstract available.

8.

Altered acetylation in polyglutamine disease: an opportunity for therapeutic intervention?

Taylor JP, Fischbeck KH.

Trends Mol Med. 2002 May;8(5):195-7.

PMID:
12067622
10.

Therapeutic opportunities in polyglutamine disease.

Hughes RE, Olson JM.

Nat Med. 2001 Apr;7(4):419-23. Review.

PMID:
11283667
12.

Quality control of the proteins associated with neurodegenerative diseases.

Gao X, Hu H.

Acta Biochim Biophys Sin (Shanghai). 2008 Jul;40(7):612-8. Review.

13.
14.

Protein-misfolding diseases and chaperone-based therapeutic approaches.

Chaudhuri TK, Paul S.

FEBS J. 2006 Apr;273(7):1331-49. Review.

15.

Polyglutamine-mediated neurodegeneration: use of chaperones as prevention strategy.

Paul S.

Biochemistry (Mosc). 2007 Apr;72(4):359-66. Review.

PMID:
17511600
16.

The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies.

Bauer PO, Nukina N.

J Neurochem. 2009 Sep;110(6):1737-65. doi: 10.1111/j.1471-4159.2009.06302.x. Epub 2009 Jul 23. Review.

17.

[Aggregation and toxicity of the proteins with polyQ repeats].

Le┼║nicki P.

Postepy Biochem. 2005;51(2):215-22. Review. Polish.

PMID:
16209359
18.

The pathogenic agent in Drosophila models of 'polyglutamine' diseases.

McLeod CJ, O'Keefe LV, Richards RI.

Hum Mol Genet. 2005 Apr 15;14(8):1041-8. Epub 2005 Mar 9.

PMID:
15757976
19.

What transgenic mice tell us about neurodegenerative disease.

Gurney ME.

Bioessays. 2000 Mar;22(3):297-304. Review.

PMID:
10684590
20.

The role of molecular chaperones in human misfolding diseases.

Broadley SA, Hartl FU.

FEBS Lett. 2009 Aug 20;583(16):2647-53. doi: 10.1016/j.febslet.2009.04.029. Epub 2009 Apr 23. Review.

Supplemental Content

Support Center